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Purpose: To assess the role of endoscopic ultrasound (EUS) in the initial evaluation and follow-up of
incidental pancreatic cystic lesions (PCL).
Methods: Retrospective analysis of patients with incidental PCL on imaging who were evaluated by EUS
and had a minimal follow-up of 1 year.
Results: There were 62 patients (40 females and 22 males). The mean patient age was 67.7 years (range,
30–89). The Median follow-up was 24 months (range, 12–72). The mean PCL size was 21.6 mm. In all, 13
patients underwent surgery (20.9%). Diagnosis included a mucinous cystic tumour (7), mucinous adeno-
carcinoma (2), intraductal papillary mucinous neoplasm (1) and a cystic neuroendocrine tumour (1). The
overall malignancy rate among patients who underwent surgery was 15.3% (two patients). The mean
carcinoembryonic antigen (CEA) level from PCL fluid analysis was also significantly higher in surgically
treated group (7760) vs. the stable group (184.7) vs. the enlarging PCL group (361.1). A CEA level above
192 ng/ml predicted mucinous PCL with a sensitivity of 90%.
Conclusions: EUS with cystic fluid analysis can be successfully used to rule out pancreatic neoplasms
and to follow-up incidentally discovered PCL.
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The ubiquitous use of cross-sectional imaging has led to the dis-
covery of incidental pancreatic cystic lesions (PCL) in about
1–1.2% of all studied populations.1 Among other pancreatic cysts,
pancreatic cystic neoplasms are encountered in 10–15% and may
represent malignant or premalignant entities.2 Endoscopic ultra-
sound (EUS) and cystic fluid analysis have become powerful tools
in the differential diagnosis of incidental PCL. Relatively few
studies have described the natural history of PCLs, not related to
acute or chronic pancreatitis. In the present study, the results of
analysis of our retrospective study of patients with PCL followed
by EUS and cystic fluid analysis are presented.
Materials and methods
Patients, who have been found to have incidentally discovered
PCLs on imaging [computed tomography (CT) or magnetic reso-
nance imaging (MRI)] done for unrelated reasons, were retro-
spectively identified in the hospital database. Patients with a
current or past history of pancreatitis were excluded. Only
patients with the above-mentioned findings who underwent EUS
with cystic fluid analysis and minimum follow-up of 1 year were
selected for analysis. The current study was approved by the
Danbury Hospital Institutional Review Board.
All patients were evaluated according to previously established
protocol (Fig. 1). The procedure included EUS with fine needle
aspiration (FNA). Cystic fluid was sent for carcinoembryonic
antigen (CEA) and cytology. If there were findings suggesting
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neoplasm during initial EUS (CEA elevated above 192 ng/ml,
presence of malignant cells on cytology or/and solid mass),
patients were referred to a HPB surgeon for possible resection.
Otherwise, patients with PCL underwent pancreas-specific MRI
or CT every 6–12 months. In cases where the PCL increased in
size, EUS was repeated and a decision made depending on
updated findings.
Results
There were 62 patients (40 females and 22 males). All patients
were asymptomatic. The mean patient age was 67.7 years (range,
30–89). The median follow-up was 24 months (range, 12–72).
Overall, 22 cystic lesions were located in the area of the pancreatic
head (35.4%), 20 cystic lesions were located in the body of pan-
creas (32.2%) and 20 in the pancreatic tail (32.2%). Mean PCL
size was 21.6 mm (range, 6–51 mm). Mean cystic CEA level was
2166 (range, 0.4–32056) ng/ml. Cytology was negative in the
majority of the specimens and positive for adenocarcinoma in one
patient in which initial EUS demonstrated a solid component
within a cystic mass. In 41 (66.1%) patients, PCL were character-
ized as non-mucinous (CEA < 192 ng/ml), remained stable and
did not require surgical evaluation. EUS was repeated in eight
cases (12.9%) as a result of an increase in size. In patients with
enlarging PCL, the mean CEA level value was 361.1, characteristic
for mucinous neoplasms. This group included patients who were
not resected because of severe co-morbidities or refusal of surgical
resection. Thirteen patients or 20.9% underwent surgery and neo-
plastic PCL were found in 11 patients (84.6%) and included nine
mucinous cystic tumours (seven mucinous cystic neoplasms and
two mucinous cystic adenocarcinomas), one case of an intraduc-
tal papillary mucinous neoplasm (IPMN), one serous cystad-
enoma, one lymphoepithelial cyst and one low grade
neuroendocrine cystic neoplasm. The cystic fluid CEA was
elevated above the cut-off value in all but one resected patient
with confirmed diagnosis of mucinous cystic neoplasm, resulting
in overall sensitivity of 90% and specificity of 84%, positive pre-
dictive value (PPV) of 90%, negative predicted value (NPV) of
66% and accuracy of 84%. The role of cytology was limited in the
present study, with a sensitivity of only 50% for cancer (positive in
one out of two cases of cystadenocarcinoma). The overall malig-
nancy rate among patients who underwent surgery was 15.3%
(two patients).
There were nine distal pancreatectomies, two pancre-
atoduodenectomies, one median pancreatectomy and one explor-
atory laparotomy (as a result of unresectable pancreatic cancer
found intra-operatively) performed. There was no mortality
among resected patients. Details of the patients who underwent
surgical resection are presented in Table 1. The mean PCL size was
larger in the surgical group (27.8 mm) vs. the stable group
(18.8 mm) vs. the enlarging PCL group (17.8 mm). The mean cyst
fluid CEA level was also significantly higher in the surgically
treated group (mean, 7760) vs. the stable group (184.7) vs. the
enlarging group (361.1).
Discussions
Pancreatic cystic neoplasms represent up to 15% of all incidental
PCL. According to the WHO classification, pancreatic cystic neo-
plasms are further divided into serous cystic neoplasms, mucinous
cystic neoplasms, intraductal papillary mucinous neoplasms and
solitary pseudopapillary neoplasms.1 Malignant potential is quite
variable, with up to 42% of the cystic neoplasms having prema-
lignant changes and up to 17% harbouring in situ cancer.1 The
group-specific malignancy rate is from 6% to 36% in cases of
mucinous cystic neoplasms, 65% to 46% in branch-type IPMN
and 60% to 92% in main duct-type IPMN.2 Taking into account
that roughly 50% of all cystic neoplasms are completely asymp-
tomatic, appropriate evaluation and follow-up are important.
EUS with FNA and cystic fluid analysis is currently the state-of-art
of evaluation in the case of the suspected pancreatic cystic neo-
plasms. With an overall complication rate of 1–2%, it allows for
differentiation between neoplastic and non-neoplastic cysts if the
amount of aspirated fluid is sufficient for analysis.3,4 Among the
most powerful markers, CEA has a pooled sensitivity of 75% and
specificity of 84% if using a level of >192 ng/ml as a cut-off value
for detection of mucinous neoplasms.5 Levels <5 ng/ml suggest
non-mucinous cyst- serous or pseudocyst. EUS characteristics of
the cystic lesions: microcystic vs. macrocystic, monocystic vs.
‘honeycomb’ appearance, presence of stellate scar, associated
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Figure 1 Protocol for management of incidental pancreatic cystic
lesions
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mural nodule or solid component and presence of pancreatic duct
dilatation) can provide additional diagnostic information. Cytol-
ogy is specific but has a low sensitivity.6 The presence of mucin,
cystic fluid CA19-9 levels, k-ras mutation and DNA analysis could
enhance diagnostic value of the PCL aspirate but is not available at
all institutions.7 In univariate analysis of 153 patients who under-
went EUS for suspected pancreatic cystic neoplasms, older age,
male gender, jaundice, a history of another malignancy, associated
solid component and positive cytology were associated with an
increased risk of cancer.8 All mucinous cystic neoplasms should be
resected if feasible. In the case of IPMN, consensus guidelines
recommend resection in the case of main pancreatic duct dilata-
tion >10 mm, branch size lesions >3 cm in diameter, a presence of
a mural nodule or cytology suspicious for malignancy.9,10 All
symptomatic lesions should be also resected. The size of lesions is
not always valid criteria in decision making because even smaller
lesions can have malignant potential.11
In spite of the the fact that PCL can be adequately imaged using
conventional CT/MRI protocols, EUS has a significant advantage
in its ability to perform guided FNA for subsequent cystic fluid
analysis. It was decided to use a CEA cut-off value of 192 ng/ml in
the present study because it correlates better than EUS morphol-
ogy or cytology in differentiating between mucinous and non-
mucinous cystic lesions.5 In the present study, a pre-determined
CEA cut-off level resulted in an ability to diagnose mucinous
cystic neoplasm with high sensitivity and specificity (90% and
84%, respectively). All PCL with a CEA level below the cut-off
value remained stable within the follow-up period.
In conclusion, EUS with FNA can be successfully used for initial
work up and follow-up of incidental pancreatic lesions and allows
for differentiation of neoplastic from non-neoplastic cysts. The
cystic fluid CEA levels >192 ng/ml can be used to reliably distin-
guish between mucinous and non-mucinous PCL.
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